New Charter Seeks to Build Global Support for Tolerance and Religious Freedom
10.12.2019 16:13:00 EET | Business Wire | Press release
This week some of the world’s most respected Islamic scholars, joined by experts from governments, civil society groups and other faiths, will launch a new effort to build global peace, based on tolerance and religious freedom.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005594/en/
New Charter Seeks to Build Global Support for Tolerance and Religious Freedom (Photo: AETOSWire)
At the sixth Assembly of the Forum for Promoting Peace in Muslim Societies, in Abu Dhabi, Shaykh Abdullah bin Bayyah, President of the Forum, will inaugurate the charter of the “New Alliance of Virtue”. Its text will be revealed and signed by its first signatories.
The charter aims to elevate religious freedom, cooperation, and tolerance from mere possibilities to necessary ethical commitments and legal obligations, especially in relation to the protection of places of worship whose attacks have threatened freedom of religion in many parts of the world.
This initiative draws direct inspiration from the earliest traditions of Islam.
The original Alliance of Virtue (hilf al-fudul) was established in early 7th century AD (late 1st century BH) Mecca, in the house of Abdullah ibn Judan.
Its purpose was to defend the weak and the innocent against the rapaciousness of those more powerful.
The Prophet of Islam, Mohammad, and the first of the Rightly Guided Caliphs, Abu Bakr, were both present when the Alliance was formed, though it was before Mohammad’s prophethood. He later praised it, saying: “I was present in the house of Ibn Judan when an alliance was formed, and were I to have been called upon by it in Islam, I would have answered its call.”
Last February in Washington D.C., H.E. Shaykh Abdullah bin Bayyah, President of the Forum for Promoting Peace, led a panel of over 200 individuals from the three Abrahamic faiths and others, comprising religious leaders and senior politicians in creating the modern Alliance of Virtue between religions.
The charter of the New Alliance of Virtue follows the model of the original, on a global scale. It brings together those of good-will for the benefit of humanity, an effort across religions to enable its members to live side-by-side in peace and happiness.
The charter doesn’t aim to bridge theological differences, members will instead cooperate based on a common theology of God-given human dignity, seeking virtue for the benefit of all.
Notes for Editors
The Forum for Promoting Peace in Muslim Societies is led by Shaykh Abdullah bin Bayyah, under the patronage of His Highness Sheikh Abdullah bin Zayed Al Nahyan, Minister for Foreign Affairs and International Cooperation. The Forum mines the best global Islamic scholarly expertise for solutions to the challenge of securing global peace. The Forum seeks to extinguish the fire of extremism that has spread throughout the world, with violence driven by erroneous and ill-informed interpretations of Islam. Participants will discuss and devise ways to challenge the extremism and politicisation which causes immense division and suffering.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005594/en/
Contact information
Forum for Promoting Peace in Muslim Societies
Zeshan Zafar, Executive Director, zeshan@peacems.com.
http://www.peacems.com/en/default.aspx
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
